Professional Information
Accreditations and Certifications
Critical Call List (PDF)
Specimen Collection/Containers
Testing Turnaround
Laboratory Services
Lab Request Form
Client Services
Cytopathology Services
Laboratory Services
Phlebotomy Services
Lab Test Directory
| UWHC Lab Test Details | |
|---|---|
| Test Name | Plavix VerifyNow Platelet Reactivity (PRU) Test |
| Test Code(s) | HCVNPRU |
| CPT Code(s) | 85576 |
| Methodology | Impedance |
| Clinical Information | Test results are in P2Y12 reaction units (PRU). This test measures the extent of platelet aggregation in the presence of P2Y12 inhibitor drugs such as clopidogrel (Plavix), prasugrel (Effient), ticagrelor (Brilinta) and ticlopidine (Ticlid). Patient Prep: Patients who have been treated with Glycoprotein llb/llla inhibitor drugs should not be tested until platelet function has recovered. This time period is approximately 14 days after discontinuation of drug adminstration for abciximab (ReoPro) and up to 48 hours for eptifibatide (Integrilin) and tirofiban (Aggrastat). The Verifynow PRUTest performance has been validated for hematocrit values between 33-52% and platelet counts between 119-502 K/uL. Results outside of these parameters have not been studied and PRUTest results may be affected. |
| Days Performed | Daily, 24 hours. |
| In-Lab Turnaround Time | 2 hours. |
| Stat In-Lab Turnaround Time | 1 hour. |
| Collection Requirements | |||
|---|---|---|---|
| Patient Preparation |
| ||
| Specimen | Blood | ||
| Collection Container |
| ||
| Collection Instructions | 1. Collect two light blue top tubes filled to the mark. Hand deliver to University Hospital Laboratory B4/220
Do not draw through a line containing heparin. The venipuncture must be atraumatic to avoid hemolysis and contamination with tissue factors and platelet activators. Tube must be allowed to fill completely.
| ||
| Collection Volume | See collection instructions. | ||
| Pediatric Collection Volume | See collection instructions. | ||
| Specimen Processing Requirements | |||||||
|---|---|---|---|---|---|---|---|
| Stability |
| ||||||
| Outreach Specimen Processing | Do NOT send through the pneumatic tube. Do NOT freeze, refrigerate, or centrifuge. Do NOT open tube. Transport at room temperature. | ||||||
| Specimen Transport | Hand deliver specimens to University Hospital Laboratory (B4/220) ASAP. Do NOT send through pneumatic tube. | ||||||
| Unacceptable Criteria | Hemolyzed or clotted specimens are not acceptable. A partially filled tube is NOT acceptable. | ||||||
| Interpretation | |
|---|---|
Test results are in P2Y12 reactions units (PRU). This measures the extent of platelet aggregation in the presence of P2Y12 inhibitor drugs such as clopidogrel (Plavix), prasugrel (Effient), tivagrelor (Brillinta), and ticlopidine (Ticlid). Pre-Drug reference range: 194-418 PRU P2Y12 values <194 (low end of reference range) are specific evidence of a P2Y12 inhibitor effect. Patients who have been treated with Glycoprotien llb/llla inhibitor drugs should not be tested until platelet function has recovered. This time period is approximately 14 days after discontinuation of drug adminstration for ABCiximab (ReoPro) and up to 48 hours for eptifibatide (Integrilin) and tirofiban (Aggrastat). Results should be interpreted in conjunction with other clinical and laboratory data available to the clinician. | |
| Test Limitations | The Verifynow PRUTest performance has been validated for hematocrit values between 33-52% and platelet counts between 119-502 K/uL. Results outside of these parameters have not been studied and PRUTest results may be affected. |
